@article{af3486a171fc4e76893c7e67de45dc8d,
title = "Pearls of wisdom for aspiring physicianscientist residency applicants and program directors",
abstract = "Postgraduate physician-scientist training programs (PSTPs) enhance the experiences of physician-scientist trainees following medical school graduation. PSTPs usually span residency and fellowship training, but this varies widely by institution. Applicant competitiveness for these programs would be enhanced, and unnecessary trainee anxiety relieved, by a clear understanding of what factors define a successful PSTP matriculant. Such information would also be invaluable to PSTP directors and would allow benchmarking of their admissions processes with peer programs. We conducted a survey of PSTP directors across the US to understand the importance they placed on components of PSTP applications. Of 41 survey respondents, most were from internal medicine and pediatrics residency programs. Of all components in the application, two elements were considered very important by a majority of PSTP directors: (a) having one or more first-author publications and (b) the thesis advisor's letter. Less weight was consistently placed on factors often considered more relevant for non-physician-scientist postgraduate applicants - such as US Medical Licensing Examination scores, awards, and leadership activities. The data presented here highlight important metrics for PSTP applicants and directors and suggest that indicators of scientific productivity and commitment to research outweigh traditional quantitative measures of medical school performance.",
author = "Gallagher, {Emily J.} and Rockey, {Don C.} and Kontos, {Christopher D.} and Vyas, {Jatin M.} and Brass, {Lawrence F.} and Hu, {Patrick J.} and Isales, {Carlos M.} and Ajijola, {Olujimi A.} and Rathmell, {W. Kimryn} and Conlin, {Paul R.} and Baiocchi, {Robert A.} and Kazmierczak, {Barbara I.} and Akabas, {Myles H.} and Williams, {Christopher S.}",
note = "Funding Information: research support from Intercept Pharmaceuticals, Gilead Sciences, Genfit, Sequana Medical, Galectin Therapeutics, Novo Nordisk, Pfizer, Durect, Axella Therapeutics, and Viking Therapeutics. CDK received support from ICON Clinical Research LLC for events adjudication for clinical trials. CMI reports holding stock in Pfizer and having a patent application (6410508) filed for compounds targeting the aging process. OAA reports ownership of NeuCures LLC and has filed a patent for intellectual property owned by University of California Regents in the areas of catheter ablation and neuromodulation. WKR reports an immediate family member with ownership stock in Caribou Bioscience. RAB reports advisory board income from Viracta and Atara as well as research support from CODIAK Biosciences and Prelude Therapeutics. MHA reports two patents related to inhibitors of nucleoside transporters (61751024, 61839527 [US patent US9695193]). Funding Information: This work was supported by the NIH (P30 DK123704 to DCR, P01AG036675 and T35 AG067577 to CMI) as well as the US Department of Veterans Affairs Office of Medical Research (1I01BX001426 to CSW). EJG, DCR, CDK, JMV, LFB, CMI, OAA, WKR, PPRC, RAB, BIK, and CSW serve on the Alliance for Academic Internal Medicine Research Committee. Funding Information: Rank as (choose one): Very Important - Fairly Important - Important - Slightly Important - Not at all important 4. Having a first author publication in a “high impact” journal 5. Having at least one first authored publication 6. Having multiple middle-authored publications 7. That the thesis research topic is relevant to clinical field of interest 8. MD-PhD Director{\textquoteright}s letter 9. MSPE (Dean{\textquoteright}s letter) 10. Thesis advisor{\textquoteright}s letter 11. Letters from clerkships or clinical electives 12. Department Chair letter 13. Undergraduate grades/academic performance 14. Graduate school transcript/academic performance 15. Medical school evaluation - preclinical grades 16. Medical school evaluation - clerkship grades 17. Grade or performance in Sub-I or Acting Internship 18. Step I score 19. Step II score 20. Impact of Personal Statement 21. Obtaining (awarded) independent fellowship funding (F30/F31/Foundation) 22. Attempted (applied, not awarded) to obtain independent fellowship funding (F30/F31/Foundation) 23. Service/Leadership activities 24. US citizen/permanent resident vs. visa holder status 25. AoA/Gold Humanism/ other awards 26. Commitment to a particular sub-specialty Section 3. Additional information used to evaluate applications 27. Please add comments about any of the factors above or additional factors you may consider when evaluating applicants for your program. 28. What do you view as acceptable productivity from an applicant who is NOT a graduate of an MD/PhD program (MD-Only)? (e.g., X number of 1st authored publications, X number of middle authored publications, h-index, impact of journal, review article, independent fellowship funded by a government agency or foundation, etc.) Section 4. Answer yes/no. Please explain. 29. Does your program accept international trainees? 30. Are MD-PhD applications flagged? 31. Does your program have a separate match (ERAS) number from the clinical residency program? Publisher Copyright: {\textcopyright} 2022, Gallagher et al.",
year = "2022",
month = mar,
day = "22",
doi = "10.1172/jci.insight.158467",
language = "English (US)",
volume = "7",
journal = "JCI Insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "6",
}